NCT00392288 - Efficacy and Safety of Ciclesonide (CIC) Administered Twice Daily in Pediatric Patients With Asthma. | Biotech Hunter

Enrollment

528

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

February 29, 2008

Study Completion Date

February 29, 2008

Conditions

Asthma

Interventions

DRUG

Ciclesonide

Ciclesonide MDI 40 µg BID over twelve weeks

DRUG

Ciclesonide

Ciclesonide MDI 80 µg BID over twelve weeks

DRUG

Placebo

Placebo MDI over twelve weeks

Trial Locations (6)

sanofi-aventis, US, Bridgewater

Sanofi-Aventis Hungaria, Budapest

Sanofi-Aventis, México

sanofi-aventis Poland, Warsaw

Sanofi-Aventis Administrative Office, Moscow

sanofi-aventis South Africa, Midrand